Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hematopoietic stem cell gene therapy: dead or alive?

Cole Ferguson1, Andre Larochelle, Cynthia E Dunbar

  • 1Molecular Hematopoiesis Section, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.

Trends in Biotechnology
|October 12, 2005
PubMed
Summary

Gene therapy shows great promise for treating genetic disorders using hematopoietic stem cells (HSCs). Ongoing research aims to improve safety and efficacy, balancing risks against the potential for lifelong cures.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microglial clonal dynamics and the impact of clonal hematopoiesis in autologously transplanted rhesus macaques.

Cell reports·2026
Same author

Restricting glycine uptake with bitopertin improves erythropoiesis in preclinical models of Diamond-Blackfan anemia.

Blood. Red cells & iron·2026
Same author

Clonal Selection and Evolution after Treatment of Severe Aplastic Anemia.

NEJM evidence·2026
Same author

Preparation of Targeted Lipid Nanoparticles by Insertion of Either Tetrazine-trans-Cyclooctene or Thiol-Maleimide Micelles.

Bioconjugate chemistry·2026
Same author

Clonal dynamics, tolerance, and adverse events after CD45-ADC-conditioned autologous HSPC transplantation in macaques.

Blood advances·2026
Same author

Harnessing CD5 to target chimeric antigen receptor-engineered NK cells against invasive fungal infections.

Molecular therapy : the journal of the American Society of Gene Therapy·2025

Area of Science:

  • Molecular Biology
  • Genetics
  • Medicine

Background:

  • Gene therapy offers potential for treating congenital genetic defects and acquired disorders.
  • Hematopoietic stem cells (HSCs) are key targets due to their self-renewal and differentiation capabilities.
  • Current therapies are limited for fatal diseases like certain immunodeficiencies.

Purpose of the Study:

  • To review recent advancements and clinical successes in gene therapy, particularly using HSCs.
  • To discuss the toxicity associated with insertional mutagenesis in gene therapy trials.
  • To evaluate current risk-to-benefit ratios and propose strategies for risk mitigation.

Main Methods:

  • Review of recent scientific literature and clinical trial data on HSC gene therapy.

Related Experiment Videos

  • Analysis of reported toxicities, focusing on insertional mutagenesis.
  • Assessment of risk-benefit profiles and discussion of future research directions.

    • Main Results:

    • Gene therapy has demonstrated clinical triumphs in treating certain genetic disorders.
    • Insertional mutagenesis remains a significant toxicity concern in ongoing trials.
    • Risk-benefit analyses indicate a need for improved safety protocols.

    Conclusions:

    • Despite toxicity concerns, the potential of HSC gene therapy warrants continued development.
    • Future strategies focus on enhancing safety to realize the full clinical potential.
    • The field is characterized by iterative refinement of protocols from basic research to clinical application and back.